Front. Med.Frontiers in MedicineFront. Med.2296-858XFrontiers Media S.A.10.3389/fmed.2024.1506094MedicineCorrectionCorrigendum: Patients with microscopic colitis have altered levels of inhibitory and stimulatory biomarkers in colon biopsies and sera compared to non-inflamed controlsLushnikovaAlexandra1*BohrJohan2WickbomAnna2MünchAndreas3SjöbergKlas4HultgrenOlof5WirénAnders1Hultgren HörnquistElisabeth11School of Medical Sciences, Örebro University, Örebro, Sweden2Division of Gastroenterology, Department of Medicine, Örebro University Hospital, Faculty of Medicine and Health, Örebro University, Örebro, Sweden3Department of Gastroenterology and Hepatology in Linköping, and Department of Health, Medicine, and Caring Sciences, Linköping University, Linköping, Sweden4Department of Clinical Sciences, Lund University, Department of Gastroenterology, Skåne University Hospital, Malmö, Sweden5Department of Clinical Immunology and Transfusion Medicine, Faculty of Medicine and Health, Örebro University, Örebro, Sweden
Edited and reviewed by: Luca Pastorelli, University of Milan, Italy
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
A Corrigendum on Patients with microscopic colitis have altered levels of inhibitory and stimulatory biomarkers in colon biopsies and sera compared to non-inflamed controls by Lushnikova, A., Bohr, J., Wickbom, A., Münch, A., Sjöberg, K., Hultgren, O., Wirén, A., and Hultgren Hörnquist, E. (2021). Front. Med. 8:727412. doi: 10.3389/fmed.2021.727412microscopic colitiscolorectal cancerimmune surveillanceimmune checkpointsulcerative colitisserumcolonic biopsiessection-at-acceptanceGastroenterology
In the published article, reference Rajabian et al. (2019) (54) was not cited in the article. The citation has now been inserted in the Discussion, paragraph 9, and should read:
“PD-1 is an inhibitory receptor expressed on activated T cells that has been reported to be upregulated in IBD (19, 52). In accordance with this, we also found increased expression in the colon of MC and UC patients with active disease. The opposite was seen in serum where levels of PD-1 were decreased. Reviews of the functions of soluble PD-1 (sPD-1) describe the theory that sPD-1 can out-compete membrane-bound PD-1 with regards to binding to its ligands (PD-L1, -L2, and CD80), thus blocking the expected inhibitory effects (15, 53). The reduced serum levels of PD-1 indicate that membrane-bound PD-1 can exert its effects with less competition from sPD-1, thereby exerting more inhibition of the inflammation seen in patients with IBD and MC. In line with our results in MC and UC patients, another study found increased levels of PD-L1 and PD-L2 mRNA in biopsies from UC patients compared with controls (54).”
In the published article, there was an error. Two ethical approval IDs and the date of one of the approvals from the Regional Ethics Review Board were stated incorrectly.
A correction has been made to the Ethics Statement. This sentence previously stated:
“The studies involving human participants were reviewed and approved by the Regional Ethics Review Board of Uppsala (2008-10-15, Ethical Approval ID #008/278) for the biopsy samples. For serum samples, approval was obtained from the Regional Ethics Review Boards of Lund (2006-06-29, ID #276/2006 and 2012-01-26, ID #2012/32) and Linköping (2012-09-05, ID #2015/216-3108 and 2015-02-05, ID #2015/31-31).”
The corrected sentence appears below:
“The studies involving human participants were reviewed and approved by the Regional Ethics Review Board of Uppsala (2008-10-15, Ethical Approval ID #2008/278) for the biopsy samples. For serum samples, approval was obtained from the Regional Ethics Review Boards of Lund (2006-06-29, ID #276/2006 and 2012-01-26, ID #2012/32) and Linköping (2012-09-05, ID #2012/216-31 and 2015-02-25, ID #2015/31-31).”
The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
ReferencesRajabianZKalaniFTaghilooSTehraniMRafieiAHosseini-khahZ. Over-expression of immunosuppressive molecules, PD-L1 and PD-L2, in ulcerative colitis patients. Iran J Immunol. (2019) 16:62–70. 10.22034/IJI.2019.3940730864556